UPDATE — Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

May 12, 2023

https://www.globenewswire.com/news-release/2023/05/12/2667831/0/en/UPDATE-Landos-Biopharma-Provides-Business-Update-and-Reports-First-Quarter-2023-Results.html

NEXUS Phase 2 Clinical Trial of NX-13 for Ulcerative Colitis Initiated

NEXUS Top-line Results Planned for Q4 2024

Sufficient Cash to Fund Planned Operations into First Half of 2025

Read more at globenewswire.com

Related news for (LABP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.